Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in East Asians and their comparison with other ethnic populations

Current Pharmacogenomics

Volumn 5, Issue 1, 2007, Pages 49-78

  Saito, Yoshiro ^a   Maekawa, K ^a   Ozawa, S ^a   Sawada, J ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

CYP2C19 alleles; CYP2C9 polymorphisms; CYP2D6 haplotypes; CYP3A4; UGT1A gene

Indexed keywords

CELECOXIB; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DIAZEPAM; DICLOFENAC; DRUG METABOLIZING ENZYME; FLURBIPROFEN; GENOMIC DNA; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; IBUPROFEN; IRBESARTAN; LORNOXICAM; LOSARTAN; MEPHENYTOIN; OMEPRAZOLE; PHENYTOIN; PIROXICAM; PROGUANIL; TOLBUTAMIDE; TORASEMIDE; UNINDEXED DRUG; WARFARIN;

AFRICAN AMERICAN; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ASIAN; CAUCASIAN; CHINESE; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESPONSE; ENHANCER REGION; ENZYME ACTIVITY; ENZYME STRUCTURE; ETHNIC DIFFERENCE; EXON; GENE DUPLICATION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC RECOMBINATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HISPANIC; HUMAN; JAPANESE; NEGRO; NUCLEOTIDE SEQUENCE; PACIFIC ISLANDER; POPULATION GENETICS; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33947182378     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016007780077202     Document Type: Review

References (239)

1. Ahmadi K. R.; Weale, M. E.; Xue, Z. Y.; Soranzo, N.; Yarnall, D. P.; Briley, J. D.; Maruyama, Y.; Kobayashi, M.; Wood, N. W.; Spurr, N. K.; Burns, D. K.; Roses, A. D.; Saunders, A. M. and Goldstein, D. B. (2005) A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat. Genet. 37, 84-89.
2. Akaba, K.; Kimuram, T.; Sasaki, A.; Tanabe, S.; Ikegami, T.; Hashimoto, M.; Umeda, H.; Yoshida, H.; Umetsu, K.; Chiba, H.; Yuasa, I. and Hayasaka, K. (1998) Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem. Mol. Biol. Int. 46, 21-26.
3. Allabi, A. C.; Gala, J. L.; Horsmans, Y.; Babaoglu, M. O.; Bozkurt, A.; Heusterspreute, M. and Yasar, U. (2004) Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans. Clin. Pharmacol. Ther. 76, 113-118.
4. Allabi, A. C.; Gala, J. L. and Horsmans, Y. (2005) CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet. Genomics 15, 779-786.
5. Andersson, T.; Regardh, C. G.; Dahl-Puustinen, M. L. and Bertilsson, L. (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther. Drug Monit. 12, 415-416.
6. Ando, Y.; Saka, H.; Ando, M.; Sawa, T.; Muro, K.; Ueoka, H.; Yokoyama, A.; Saitoh, S.; Shimokata, K. and Hasegawa, Y. (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926.
7. Ando, Y. and Hasegawa, Y. (2005) Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab. Rev. 37, 565-574.
8. Aono, S.; Adachi, Y.; Uyama, E.; Yamada, Y.; Keino, H.; Nanno, T.; Koiwai, O. and Sato, H. (1995) Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet 345, 958-959.
9. Bajpai, M.; Roskos, L. K.; Shen, D. D. and Levy, R. H. (1996) Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos. 24, 1401-1403.
10. Ball, S. E.; Scatina, J.; Kao, J.; Ferron, G. M.; Fruncillo, R.; Mayer, P.; Weinryb, I.; Guida, M.; Hopkins, P. J.; Warner, N. and Hall, J. (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66, 288-294.
11. Balram, C.; Sabapathy, K.; Fei, G.; Khoo, K. S. and Lee, E. J. (2002) Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 12, 81-83.
12. Balram, C.; Zhou, Q.; Cheung, Y. B. and Lee, E. J. (2003) CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur. J. Clin. Pharmacol. 59, 123-126.
13. Basu, N. K.; Ciotti, M.; Hwang, M. S.; Kole, L.; Mitra, P. S.; Cho, J. W. and Owens, I. S. (2004) Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J. Biol. Chem. 279, 1429-1441.
14. Beutler, E.; Gelbart, T. and Demina, A. (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. USA 95, 8170-8174.
15. Blaisdell, J.; Mohrenweiser, H.; Jackson, J.; Ferguson, S.; Coulter, S.; Chanas, B.; Xi, T.; Ghanayem, B. and Goldstein, J. A. (2002) Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12, 703-711.
16. Blaisdell, J.; Jorge-Nebert, L. F.; Coulter, S.; Ferguson, S. S.; Lee, S. J.; Chanas, B.; Xi, T.; Mohrenweiser, H.; Ghanayem, B. and Goldstein, J. A. (2004) Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14, 527-537.
17. Blann, A.; Hewitt, J.; Siddiqui, F. and Bareford, D. (1999) Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br. J. Haematol. 107, 207-209.
18. Bosma, P. J.; Chowdhury, J. R.; Bakker, C.; Gantla, S.; de Boer, A.; Oostra, B. A.; Lindhout, D.; Tytgat, G. N.; Jansen, P. L. and Oude Elferink, R. P. (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333, 1171-1175.
19. Boyd, M. A.; Srasuebkul, P.; Ruxrungtham, K.; Mackenzie, P. I.; Uchaipichat, V.; Stek, M. Jr.; Lange, J. M.; Phanuphak, P.; Cooper, D. A.; Udomuksorn, W.; Miners, J. O. (2006) Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet. Genomics 16, 321-329.
20. Bradford, L. D. (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-243.
21. Bravo-Villalta, H. V.; Yamamoto, K.; Nakamura, K.; Baya, A.; Okada, Y. and Horiuchi, R. (2005) Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur. J. Clin. Pharmacol. 61, 179-184.
22. Broly, F. and Meyer, U. A. (1993) Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 3, 123-130.
23. Cavaco, I.; Gil, J. P.; Gil-Berglund, E. and Ribeiro, V. (2003) CYP3A4 and MDR1 alleles in a Portuguese population. Clin. Chem. Lab. Med. 41, 1345-1350.
24. Chern, H. D.; Ueng, T. H.; Fu, Y. P. and Cheng, C. W. (2006) CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. Clin. Chim. Acta. 367, 108-113.
25. Chida, M.; Yokoi, T.; Nemoto, N.; Inaba, M.; Kinoshita, M. and Kamataki, T. (1999a) A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. Pharmacogenetics 9, 287-293.
26. Chida, M.; Yokoi, T.; Kosaka, Y.; Chiba, K.; Nakamura, H.; Ishizaki, T.; Yokota, J.; Kinoshita, M.; Sato, K.; Inaba, M.; Aoki, Y.; Gonzalez, F. J. and Kamataki, T. (1999b) Genetic polymorphism of CYP2D6 in the Japanese population. Pharmacogenetics 9, 601-605.
27. Chida, M.; Ariyoshi, N.; Yokoi, T.; Nemoto, N.; Inaba, M.; Kinoshita, M. and Kamataki, T. (2002) New allelic arrangement CYP2D6*36 × 2 found in a Japanese poor metabolizer of debrisoquine. Pharmacogenetics 12, 659-662.
28. Chowbay, B.; Cumaraswamy, S.; Cheung, Y. B.; Zhou, Q. and Lee, E. J. (2003) Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13, 99-95.
29. Chowbay, B.; Zhou, S. and Lee, E. J. (2005) An interethnic comparison of polymorphisms of the genes encoding drag-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab. Rev. 37, 327-378.
30. Ciotti, M.; Basu, N.; Brangi, M. and Owens, I. S. (1999) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem. Biophys. Res. Commun. 260, 199-202.
31. Congiu, M.; Mashford, M. L.; Slavin, J. L. and Desmond, P. V. (2002) UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab. Dispos. 30, 129-134.
32. Cubeddu, L. X.; Aranda, J.; Singh, B.; Klein, M.; Brachfeld, J.; Freis, E.; Roman, J. and Eades, T. A. (1986) comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. JAMA 256, 2214-2221.
33. Dahl, M.-L.; Yue, Q.-Y.; Roh, H.-K.; Johansson, I.; Sawe, J.; Sjoqvist, F. and Bertilsson, L. (1995) Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 5, 159-165.
34. Dai, D.; Tang, J.; Rose, R.; Hodgson, E.; Bienstock, R. J.; Mohrenweiser, H. W. and Goldstein, J. A. (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299, 825-831.
35. Dannenberg, L. O. and Edenberg, H. J. (2006) Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 19, 181.
36. DeLozier, T. C.; Lee, S. C.; Coulter, S. J.; Goh, B. C. and Goldstein, J. A. (2005) Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J. Pharmacol. Exp. Ther. 315, 1085-1090.
37. De Morais, S. M.; Wilkinson, G. R.; Blaisdell, J.; Nakamura, K.; Meyer, U. A. and Goldstein, J. A. (1994a) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419-15422.
38. De Morais, S. M.; Wilkinson, G. R.; Blaisdell, J.; Meyer, U. A.; Nakamura, K. and Goldstein, J. A. (1994b) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46, 594-598.
39. Desta, Z.; Zhao, X.; Shin, J.-G. and Flockhart, D. A. (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41, 913-958.
40. Dickmann, L. J.; Rettie, A. E.; Kneller, M. B.; Kim, R. B.; Wood, A. J.; Stein, C. M.; Wilkinson, G. R. and Schwarz, U. I. (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol. 60, 382-387.
41. Drocourt, L.; Ourlin, J. C.; Pascussi, J. M.; Maurel, P. and Vilarem, M. J. (2002) Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem. 277, 25125-25132.
42. Droll, K.; Bruce-Mensah, K.; Otton, S. V.; Gaedigk, A.; Sellers, E. M. and Tyndale, R. F. (1998) Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 8, 325-333.
43. Ebisawa, A.; Hiratsuka, M.; Sakuyama, K.; Konno, Y.; Sasaki, T. and Mizugaki, M. (2005) Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6 gene in Japanese individuals. Drug Metab. Pharmacokinet. 20, 294-299.
44. Ehmer, U.; Vogel, A.; Schutte, J. K.; Krone, B.; Manns, M. P. and Strassburg, C. P. (2004) Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39, 970-977.
45. Eiselt, R.; Domanski, T. L.; Zibat, A.; Mueller, R.; Presecan-Siedel, E.; Hustert, E.; Zanger, U. M.; Brockmoller, J.; Klenk, H. P.; Meyer, U. A.; Khan, K. K.; He, Y. A.; Halpert, J. R. and Wojnowski, L. (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11, 447-458.
46. Evans, W. E. and Relling, M. V. (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491.
47. Ferguson, R. J.; De Morais, S. M.; Benhamou, S.; Bouchardy, C.; Blaisdell, J.; Ibeanu, G.; Wilkinson, G. R.; Sarich, T. C.; Wright, J. M.; Dayer, P. and Goldstein, J. A. (1999) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther. 284, 356-361.
48. Fertrin, K. Y.; Goncalves, M. S.; Saad, S. T. and Costa, F. F. (2002) Frequencies of UDP-glucuronosytransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am. J. Med. Genet. 108, 117-119.
49. Finel, M.; Li, X.; Gardner-Stephen, D.; Bratton, S.; Mackenzie, P. I. and Radominska-Pandya, A. (2005) Human UDP-glucuronosyltransferase 1A5: identification, expression, and activity. J. Pharmacol. Exp. Ther. 315, 1143-1149.
50. Fukuda, T.; Nishida, Y.; Imaoka, S.; Hiroi, T.; Naohara, M.; Funae, Y. and Azuma, J. (2000) The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch. Biochem. Biophys. 380, 303-308.
51. Fukuda, T.; Maune, H.; Ikenaga, Y.; Naohara, M.; Fukuda, K. and Azuma, J. (2005) Novel structure of the CYP2D6 gene that confuses genotyping for the CYP2D6*5 allele. Drug Metab. Pharmacokinet. 20, 345-350.
52. Fukuen, S.; Fukuda, T.; Maune, H.; Ikenaga, Y.; Yamamoto, I.; Inaba, T. and Azuma, J. (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12, 331-334.
53. Fukushima-Uesaka, H.; Saito, Y.; Watanabe, H.; Shiseki, K.; Saeki, M.; Nakamura, T.; Kurose, K.; Sai, K.; Komamura, K.; Ueno, K.; Kamakura, S.; Kitakaze, M.; Hanai, S.; Nakajima, T.; Matsumoto, K.; Saito, H.; Goto, Y.; Kimura, H.; Katoh, M.; Sugai, K.; Minami, N.; Shirao, K.; Tamura, T.; Yamamoto, N.; Minami, H.; Ohtsu, A.; Yoshida, T.; Saijo, N.; Kitamura, Y.; Kamatani, N.; Ozawa, S. and Sawada, J. (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat. 23, 100.
54. Fukushima-Uesaka, H.; Saito, Y.; Maekawa, K.; Ozawa, S.; Hasegawa, R.; Kajio, H.; Kuzuya, N.; Yasuda, K.; Kawamoto, M.; Kamatani, N.; Suzuki, K.; Yanagawa, T.; Tohkin, M. and Sawada, J. (2005) Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab. Pharmacokinet. 20, 300-307.
55. Furuta, T.; Shirai, N.; Sugimoto, M.; Nakamura, A.; Hishida, A. and Ishizaki, T. (2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab. Pharmacokinet. 20, 153-167.
56. Gaedigk, A.; Bradford, L. D.; Alander, S. W. and Leeder, J. S. (2006) CYP2D6*36 gene arrangements within the CYP2D6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab. Dispos. 34, 563-569.
57. Gagne, J. F.; Montminy, V.; Belanger, P.; Journault, K.; Gaucher, G. and Guillemette, C. (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl10-hydroxycamptothecin (SN-38). Mol. Pharmacol. 62, 608-617.
58. Garcia-Barcelo, M.; Chow, L. Y.; Kum Chiu, H. F.; Wing, Y. K.; Shing Lee, D. T.; Lam, K. L. and Waye, M. M. (1999) Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection ofthe rare allele CYP2C19*4. Clin. Chem. 45, 2273-2274.
59. Garcia-Barcelo, M.; Chow, L. Y.; Chiu, H. F.; Wing, Y. K.; Lee, D. T.; Lam, K. L. and Waye, M. M. (2000a) Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin. Chem. 46, 18-23.
60. Garcia-Barcelo, M.; Chow, L. Y.; Lam, K. L.; Chiu, H. F.; Wing, Y. K. and Waye, M. M. (2000b) Occurrence of CYP2D6 gene duplication in Hong Kong Chinese. Clin. Chem. 46, 1411-1413.
61. Garcia-Martin, E.; Martinez, C.; Ladero, J. M. and Agundez, J. A. (2006) Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol. Diagn. Ther. 10, 29-40.
62. Garsa, A. A.; McLeod, H. L. and Marsh, S. (2005) CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med. Genet. 6, 19.
63. Gellner, K.; Eiselt, R.; Hustert, E.; Arnold, H.; Koch, I.; Haberl, M.; Deglmann, C. J.; Burk, O.; Buntefuss, D.; Escher, S.; Bishop, C.; Koebe, H. G.; Brinkmann, U.; Klenk, H. P.; Kleine, K.; Meyer, U. A. and Wojnowski, L. (2001) Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11, 111-121.
64. Goldstein, J. A. and de Morais, S. M. (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4, 285-299.
65. Goodwin, B.; Hodgson, E. and Liddle, C. (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329-1339.
66. Goodwin, B.; Hodgson, E.; D'Costa, D. J.; Robertson, G. R. and Liddle, C. (2002) Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol. 62, 359-365.
67. Grant D. M. (2005) Technologies for the analysis of single nucleotide polymorphisms-an overview. In Pharmacogenomics: Second Edition; Kalow, W.; Meyer, U. A.; Tyndale, R. F.; Eds.; Taylor and Francis Group: Boca Raton, FL, pp. 305-312.
68. Griese, E.-U.; Zanger, U. M.; Brudermanns, U; Gaedigk, A.; Mikus, G.; Morike, K.; Stuven, T. and Eichelbaum, M. (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8, 5-26.
69. Guengerich, F. P. (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1-17.
70. Guillemette, C.; Millikan, R. C.; Newman, B. and Housman, D. E. (2000a) Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res. 60, 950-956.
71. Guillemette, C.; Ritter, J. K.; Auyeung, D. J.; Kessler, F. K. and Housman, D. E. (2000b) Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10, 629-644.
72. Guillemette, C. (2003) Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3, 136-158.
73. Guo, Y.; Zhang, Y.; Wang, Y.; Chen, X.; Si, D.; Zhong, D.; Fawcett, J. P. and Zhou, H. (2005a) Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab. Dispos. 33, 749-753.
74. Guo, Y.; Wang, Y.; Si, D.; Fawcett, P. J.; Zhong, D. and Zhou, H. (2005b) Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 35, 853-861.
75. Hall, D.; Ybazeta, G.; Destro-Bisol, G.; Petzl-Erler, M. L. and Di Rienzo, A. (1999) Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 9, 591-599.
76. Han, J. Y.; Lim, H. S.; Shin, E. S.; Yoo, Y. K.; Park, Y. H.; Lee, J. E.; Jang, I. J.; Lee, D. H. and Lee, J. S. (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237-2244.
77. Handschin, C. and Meyer, U. A. (2003) Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 55, 649-673.
78. Hanioka, N.; Okumura, Y.; Saito, Y.; Hichiya, H.; Soyama, A.; Saito, K.; Ueno, K.; Sawada, J. and Narimatsu, S. (2006). Catalytic roles of CYP2D6.10 and CYP2D6.36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae. Biochem. Pharmacol. 71, 1386-1395.
79. Herman, D.; Peternel, P.; Stegnar, M.; Breskvar, K. and Dolzan, V. (2006) A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) in a patient on warfarin therapy. Thromb. Haemost. 95, 192-194.
80. Hersberger, M.; Marti-Jaun, J.; Rentsh, K. and Hanseler, E. (2000) Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin. Chem. 46, 1072-1077.
81. Hesselink, D. A.; van Gelder, T.; van Schaik, R. H.; Balk, A. H.; van der Heiden, I. P.; van Dam, T.; van der Werf, M.; Weimar, W. and Mathot, R. A. (2004) Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther. 76, 545-556.
82. Higashi, M. K.; Veenstra, D. L.; Kondo, L. M.; Wittkowsky, A. K.; Srinouanprachanh, S. L.; Farin, F. M. and Rettie, A. E. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698.
83. Hiratsuka, M.; Takekuma, Y.; Endo, N.; Narahara, K.; Hamdy, S. I.; Kishikawa, Y.; Matsuura, M.; Agatsuma, Y.; Inoue, T. and Mizugaki, M. (2002) Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur. J. Clin. Pharmacol. 58, 417-421.
84. Hirota, T.; Ieiri, I.; Takane, H.; Maegawa, S.; Hosokawa, M.; Kobayashi, K.; Chiba, K.; Nanba, E.; Oshimura, M.; Sato, T.; Higuchi, S. and Otsubo, K. (2004) Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Hum. Mol. Genet. 13, 2959-2969.
85. Hsieh, K. P.; Lin, Y. Y.; Cheng, C. L.; Lai, M. L.; Lin, M. S.; Siest, J. P. and Huang, J. D. (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos. 29, 268-273.
86. Huang, C. S.; Chang, P. F.; Huang, M. J.; Chen, E. S.; Hung, K. L. and Tsou, K. I. (2002) Relationship between bilirubin UDP-glucuronosyl transferase 1A1 gene and neonatal hyperbilirubinemia. Pediatr. Res. 52, 601-605.
87. Huang, M. J.; Yang, S. S.; Lin, M. S. and Huang, C. S. (2005) Polymorphisms of uridine-diphosphoglucuronosyltransferase 1A7 gene in Taiwan Chinese. World J. Gastroenterol. 11, 797-802.
88. Hustert, E.; Haberl, M.; Burk, O.; Wolbold, R.; He, Y. Q.; Klein, K.; Nuessler, A. C.; Neuhaus, P.; Klattig, J.; Eiselt, R.; Koch, I.; Zibat, A.; Brockmoller, J.; Halpert, J. R.; Zanger, U. M. and Wojnowski, L. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11, 773-779.
89. Ibeanu, G. C.; Goldstein, J. A.; Meyer, U.; Benhamou, S.; Bouchardy, C.; Dayer, P.; Ghanayem, B. I. and Blaisdell, J. (1998) Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharmacol. Exp. Ther. 286, 1490-1495.
90. Ibeanu, G. C.; Blaisdell, J.; Ferguson, R. J.; Ghanayem, B. I.; Brosen, K.; Benhamou, S.; Bouchardy, C.; Wilkinson, G. R.; Dayer, P. and Goldstein, J. A. (1999) A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J. Pharmacol. Exp. Ther. 290, 635-640.
91. Ieiri, L; Tainaka, H.; Morita, T.; Hadama, A.; Mamiya, K.; Hayashibara, M.; Ninomiya, H.; Ohmori, S.; Kitada, M.; Tashiro, N.; Higuchi, S. and Otsubo, K. (2000) Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther. Drug Monit. 22, 237-244.
92. Ikenaga, Y.; Fukuda, T.; Fukuda, K.; Nishida, Y.; Naohara, M.; Maune, H. and Azuma, J. (2005) The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution. Drug Metab. Pharmacokinet. 20, 113-116.
93. Imai, J.; Ieiri, I.; Mamiya, K.; Miyahara, S.; Furuumi, H.; Nanba, E.; Yamane, M.; Fukumaki, Y.; Ninomiya, H.; Tashiro, N.; Otsubo, K. and Higuchi, S. (2000) Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10, 85-89.
94. Ingelman-Sundberg, M. (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-13.
95. Innocenti, F.; Grimsley, C.; Das, S.; Ramirez, J.; Cheng, C.; Kuttab-Boulos, H.; Ratain, M. J. and Di Rienzo, A. (2002) Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12, 725-733.
96. Innocenti, F.; Liu, W.; Chen, P.; Desai, A. A.; Das, S. and Ratain, M. J. (2005) Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet. Genomics 15, 295-301.
97. Inomata, S.; Nagashima, A.; Itagaki, F.; Homma, M.; Nishimura, M.; Osaka, Y.; Okuyama, K.; Tanaka, E.; Nakamura, T.; Kohda, Y.; Naito, S.; Miyabe, M. and Toyooka, H. (2005) CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin. Pharmacol. Ther. 78, 647-655.
98. Inoue, K.; Yamazaki, H.; Imiya, K.; Akasaka, S.; Guengerich, F. P. and Shimada, T. (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7, 103-113.
99. Ishiguro, A.; Kubota, T.; Sasaki, H.; Yamada, Y. and Iga, T. (2003) Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population. Br. J. Clin. Pharmacol. 55, 414-415.
100. Ishiguro, A.; Kubota, T.; Ishikawa, H. and Iga, T. (2004a) Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity. Clin. Chim. Acta 344, 201-204.
101. Ishiguro, A.; Kubota, T.; Sasaki, H. and Iga, T. (2004b) A long PCR assay to distinguish CYP2D6*5 and a novel CYP2D6 mutant allele associated with an 11-kb EcoRI haplotype. Clin. Chim. Acta 347, 217-221.
102. Iwai, M.; Maruo, Y.; Ito, M.; Yamamoto, K.; Sato, H. and Takeuchi, Y. (2004) Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J. Hum. Genet. 49, 123-128.
103. Ji, L.; Pan, S.; Marti-Jaun, J.; Hanseler, E.; Rentsch, K. and Hersberger, M. (2002a) Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin. Chem. 48, 983-988.
104. Ji, L.; Pan, S.; Wu, J.; Marti-Jaun, J. and Hersberger, M. (2002b) Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin. Med. J. 115, 1780-1784.
105. Jinno, H.; Tanaka-Kagawa, T.; Hanioka, N.; Saeki, M.; Ishida, S.; Nishimura, T.; Ando, M.; Saito, Y.; Ozawa, S. and Sawada, J. (2003a) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab. Dispos. 31, 108-113.
106. Jinno, H.; Saeki, M.; Tanaka-Kagawa, T.; Hanioka, N.; Saito, Y.; Ozawa, S.; Ando, M.; Shirao, K.; Minami, H.; Ohtsu, A.; Yoshida, T.; Saijo, N. and Sawada, J. (2003b) Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10. Drug Metab. Dispos. 31, 528-532.
107. Johansson, I.; Oscarson, M.; Yue, Q. Y.; Bertilsson, L.; Sjoqvist, F. and Ingelman-Sundberg, M. (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine bydroxylation. Mol. Pharmacol. 46, 452-459.
108. Judson, R.; Stephens, J. C. and Windemuth, A. (2000) The predictive power of haplotypes in clinical response. Pharmacogenomics 1, 15-26.
109. Kagimoto, M.; Heim, M.; Kagimoto, K.; Zeugin, T. and Meyer, U. A. (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J. Biol. Chem. 265, 17209-17214.
110. Kanai, M.; Kijima, K.; Shirahata, E.; Sasaki, A.; Akaba, K.; Umetsu, K.; Tezuka, N.; Karachi, H.; Aikawa, S. and Hayasaka, K. (2005) Neonatal hyperbilirubinemia and the bilirubin uridine diphosphateglucuronosyltransferase gene: the common -3263T > G mutation of phenobarbital response enhancer module is not associated with the neonatal hyperbilirubinemia in Japanese. Pediatr. Int. 47, 137-141.
111. Kaniwa, N.; Kurose, K.; Jinno, H.; Tanaka-Kagawa, T.; Saito, Y.; Saeki, M.; Sawada, J.; Tohkin, M. and Hasegawa, R. (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab. Dispos. 33, 458-465.
112. Ki, C. S.; Lee, K. A.; Lee, S. Y.; Kim, H. J.; Cho, S. S.; Park, J. H.; Cho, S.; Sohn, K. M. and Kim, J. W. (2003) Haplotype structure of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and its relationship to serum total bilirubin concentration in a male Korean population. Clin. Chem. 49, 2078-2081.
113. Kidd, R. S.; Curry, T. B.; Gallagher, S.; Edeki, T.; Blaisdell, J. and Goldstein, J. A. (2001) Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11, 803-808.
114. King, B. P.; Khan, T. I.; Aithal, G. P.; Kamali, F. and Daly, A. K. (2004) Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 14, 813-822.
115. Kirchheiner, J.; Nickchen, K.; Bauer, M.; Wong, M. L.; Licinio, J.; Roots, I. and Brockmoller, J. (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 442-473.
116. Kirchheiner, J. and Brockmoller, J. (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77, 1-16.
117. Kittles, R. A.; Chen, W.; Panguluri, R. K.; Ahaghotu, C.; Jackson, A.; Adebamowo, C. A.; Griffin, R.; Williams, T.; Ukoli, F.; Adams-Campbell, L.; Kwagyan, J.; Isaacs, W.; Freeman, V. and Dunston, G. M. (2002) CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum. Genet. 110, 553-560.
118. Kohle, C.; Mohrle, B.; Munzel, P. A.; Schwab, M.; Wernet, D.; Badary, O. A. and Bock, K. W. (2003) Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGTlA6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem. Pharmacol. 65, 1521-1527.
119. Krishna, D. R. and Shekar, M. S. (2005) Cytochrome P450 3A: genetic polymorphisms and inter-ethnic differences. Methods Find. Exp. Clin. Pharmacol. 27, 559-567.
120. Krishnaswamy, S.; Hao, Q.; Al-Rohaimi, A.; Hesse, L. M.; von Moltke, L. L.; Greenblatt, D. J. and Court, M. H. (2005) UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J. Pharmacol. Exp. Ther. 313, 1340-1346.
121. Kubota, T; Yamaura, Y.; Ohkawa, N.; Hara, H. and Chiba, K. (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol. 50, 31-34.
122. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P. B.; Daly, A.; Wrighton, S. A.; Hall, S. D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M. S. and Schuetz, E. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391.
123. Lamba, J. K.; Lin, Y. S.; Thummel, K.; Daly, A.; Watkins, P. B.; Strom, S.; Zhang, J. and Schuetz, E. G. (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12, 121-132.
124. Lampe, J. W.; Bigler, J.; Horner, N. K. and Potter, J. D. (1999) UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 9, 341-349.
125. Lee, C. R.; Goldstein, J. A. and Pieper, J. A. (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12, 251-263.
126. Lee, S. J. and Goldstein, J. A. (2005) Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 6, 357-371.
127. Lee, S. J.; Bell, D. A.; Coulter, S. J.; Ghanayem, B. and Goldstein, J. A. (2005) Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J. Pharmacol. Exp. Ther. 313, 302-309.
128. Lee, S.-Y.; Sohn, K. M.; Ryu, J. Y.; Yoon, Y. R.; Shin, J. G. and Kim, J.-W. (2006a) Sequence-based CYP2D6 genotyping in the Korean population. Ther. Drug Monit. 28, 382-387.
129. Lee, S. C.; Ng, S. S.; Oldenburg, J.; Chong, P. Y.; Rost, S.; Guo, J. Y.; Yap, H. L.; Rankin, S. C.; Khor, H. B.; Yeo, T. C.; Ng, K. S.; Soong, R. and Goh, B. C. (2006b) Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79, 197-205.
130. Le Meur, Y.; Djebli, N.; Szelag, J. C.; Hoizey, G.; Toupance, O.; Rerolle, J. P. and Marquet, P. (2006) CYP3A5*3 influences sirolimus oral clearance in de nova and stable renal transplant recipients. Clin. Pharmacol. Ther. 80, 51-60.
131. Lewis, D. F.; Dickins, M.; Weaver, R. J.; Eddershaw, P. J.; Goldfarb, P. S. and Tarbit, M. H. (1998) Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. Xenobiotica 28, 235-268.
132. Liu, C. H.; Peck, K.; Huang, J. D.; Lin, M. S.; Wang, C. H.; Hsu, W. P.; Wang, H. W.; Lee, H. L. and Lai, M. L. (2005) Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics 6, 731-747.
133. Luo, H. R.; Gaedigk, A.; Aloumanis, V. and Wan, Y. J. (2005)
134. Mackenzie, P. I.; Walter Bock, K.; Burchell, B.; Guillemette, C.; Ikushiro, S.; Iyanagi, T.; Miners, J. O.; Owens, I. S. and Nebert, D. W. (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics 15, 677-685.
135. Maekawa, K.; Fukushima-Uesaka, H.; Tohkin, M.; Hasegawa, R.; Kajio, H.; Kuzuya, N.; Yasuda, K.; Kawamoto, M.; Kamatani, N.; Suzuki, K.; Yanagawa, T.; Saito, Y. and Sawada, J. (2006) Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet. Genomics 16, 497-514.
136. Maitland, M. L.; Grimsley, C.; Kuttab-Boulos, H.; Witonsky, D.; Kasza, K. E.; Yang, L.; Roe, B. A. and Di Rienzo, A. (2006) Comparative genomics analysis of human sequence variation in the UGT1A gene cluster. Pharmacogenomics J. 6, 52-62.
137. Mamiya, K.; Ieiri, L; Miyahara, S.; Imai, J.; Furuumi, H.; Fukumaki, Y.; Ninomiya, H.; Tashiro, N.; Yamada, H. and Higuchi, S. (1998) Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients. Pharmacogenetics 8, 87-90.
138. Marcucci, K. A.; Pearce, R. E.; Crespi, C.; Steimel, D. T.; Leeder, J. S. and Gaedigk, A. (2002) Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab. Dispos. 30, 595-601.
139. Marez, D.; Legrand, M.; Sabbagh, N.; Guidice, J. M.; Spire, C.; Lafitte, J. J.; Meyer, U. A. and Broly, F. (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7, 193-202.
140. Marsh, S. and McLeod, H. L. (2004) Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 5, 835-843.
141. Masimirembwa, C.; Persson, I.; Bertilsson, L.; Hasler, J. and Ingelman-Sundberg, M. (1996) A novel mutant variant of the CYP2D6 gene (CYP2D6*7) common in a black African population: association with diminished debrisoquine hydxylase activity. Br. J. Clin. Pharmacol. 42, 713-719.
142. Matsumura, K.; Saito, T.; Takahashi, Y.; Ozeki, T.; Kiyotani, K.; Fujieda, M.; Yamazaki, H.; Kunitoh, H. and Kamataki, T. (2004) Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol. Pharmacol 65, 326-334.
143. Mitsunaga, Y.; Kubota, T.; Ishiguro, A.; Yamada, Y.; Sasaki, H.; Chiba, K. and Iga, T. (2002) Frequent occurrence of CYP2D6*10 duplication allele in a Japanese population. Mutat. Res. 505, 83-85.
144. Monaghan, G.; Ryan, M.; Seddon, R.; Hume, R. and Burchell, B. (1996) Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347, 578-581.
145. Mori, A.; Maruo, Y.; Iwai, M.; Sato, H. and Takeuchi, Y. (2005) UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab. Dispos. 33, 672-675.
146. Morin, S.; Bodin, L.; Loriot, M. A.; Thijssen, H. H.; Robert, A.; Strabach, S.; Verstuyft, C.; Tregouet, D. A.; Dubert, L.; Laurent-Puig, P.; Funck-Brentano, C.; Jaillon, P.; Beaune, P. H. and Becquemont, L. (2004) Pharmacogenetics of acenocoumarol pharmacodynamics. Clin. Pharmacol. Ther. 75, 403-414.
147. Morita, J.; Kobayashi, K.; Wanibuchi, A.; Kimura, M.; Irie, S.; Ishizaki, T. and Chiba, K. (2004) A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4′-hydroxylation. Drug Metab. Pharmacokinet. 19, 236-238.
148. Murayama, N.; Nakamura, T.; Saeki, M.; Soyama, A.; Saito, Y.; Sai, K.; Ishida, S.; Nakajima, O.; Itoda, M.; Ohno, Y.; Ozawa, S. and Sawada, J. (2002) CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation. Drug Metab. Pharmacokinet. 17, 150-156.
149. Nakajima, Y.; Yoshitani, T.; Fukushima-Uesaka, H.; Saito, Y.; Kaniwa, N.; Kurose, K.; Ozawa, S.; Aoyagi, N.; Kamatani, N.; Yamamoto, N.; Kunitoh, H.; Ohe, Y.; Tamura, T.; Yoshida, T.; Minami, H.; Saijo, N.; Katori, N. and Sawada, J. (2006) Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin. Pharmacol. Ther. 80, 179-191.
150. Naoe, T.; Takeyama, K.; Yokozawa, T.; Kiyoi, H.; Seto, M.; Uike, N.; Ino, T.; Utsunomiya, A.; Maruta, A.; Jin-nai, I.; Kamada, N.; Kubota, Y.; Nakamura, H.; Shimazaki, C.; Horiike, S.; Kodera, Y.; Saito, H.; Ueda, R.; Wiemels, J. and Ohno, R. (2000) Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin. Cancer Res. 6, 4091-4095.
151. Nasu, K.; Kubota, T. and Ishizaki, T. (1997) Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7, 405-409.
152. Nishida, Y.; Fukuda, T.; Yamamoto, I. and Azuma, J. (2000) CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 10, 567-570.
153. Obayashi, K.; Nakamura, K.; Kawana, J.; Ogata, H.; Hanada, K.; Kurabayashi, M.; Hasegawa, A.; Yamamoto, K. and Horiuchi, R. (2006) VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin. Pharmacol. Ther. 80, 169-178.
154. Ozdemir, V.; Kalowa, W.; Tang, B. K.; Paterson, A. D.; Walker, S. E.; Endrenyi, L. and Kashuba, A. D. (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10, 373-388.
155. Pang, C. P.; Zhang, J.; Woo, J.; Chan, D.; Law, L. K.; Tong, S. F.; Kwok, T. and Kay, R. (1998) Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease. Mov. Disord. 13, 529-532.
156. Park, J. Y.; Kim, K. A.; Park, P. W.; Lee, O. J.; Kang, D. K.; Shon, J. H.; Liu, K. H. and Shin, J. G. (2006) Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin. Pharmacol. Ther. 79, 590-599.
157. Plummer, S. J.; Conti, D. V.; Paris, P. L.; Curran, A. P.; Casey, G. and Witte, J. S. (2003) CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 12, 928-932.
158. Premawardhena, A.; Fisher, C. A.; Liu, Y. T.; Verma, I. C.; de Silva, S.; Arambepola, M.; Clegg, J. B. and Weatherall, D. J. (2003) The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol. Dis. 31, 98-101.
159. Radominska-Pandya, A.; Czernik, P. J.; Little, J. M.; Battaglia, E. and Mackenzie, P. I. (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab. Rev. 31, 817-899.
160. Raimundo, S.; Fischer, J.; Eichelbaum, M.; Griese, E. U.; Schwab, M. and Zanger, U. M. (2000) Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10, 577-581.
161. Raimundo, S.; Toscano, C.; Klein, K.; Fischer, J.; Griese, E. U.; Eichelbaum, M.; Schwab, M. and Zanger, U. M. (2004) A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin. Pharmacol. Ther. 76, 128-138.
162. Rebbeck, T. R.; Jaffe, J. M.; Walker, A. H.; Wein, A. J. and Malkowicz, S. B. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 90, 1225-1229.
163. Rettie, A. E. and Jones, J. P. (2005) Clinical and toxicological relevance of CYP2C9: Drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol. 45, 477-494.
164. Reyes-Hernandez, O. D.; Arteaga-Illan, G. and Elizondo, G. (2004) Detection of CYP3A4*1B and CYP3A4*2 polymorphisms by RFLP. Distribution frequencies in a Mexican population. Clin. Genet. 66, 166-168.
165. Ritter, J. K.; Kessler, F. K.; Thompson, M. T.; Grove, A. D.; Auyeung, D. J. and Fisher, R. A. (1999) Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. Hepatology 30, 476-484.
166. Rodriguez-Antona, C.; Sayi, J. G.; Gustafsson, L L.; Bertilsson, L. and Ingelman-Sundberg, M. (2005) Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem. Biophys. Res. Commun. 338, 299-305.
167. Roh, H. K.; Dahl, M. L.; Johansson, I.; Ingelman-Sundberg, M.; Cha, Y. N. and Bertilsson, L. (1996) Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6, 441-447.
168. Roy, J. N.; Lajoie, J.; Zijenah, L. S.; Barama, A.; Poirier, C.; Ward, B. J. and Roger, M. (2005) CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 33, 884-887.
169. Sachse, C.; Brockmoller, J.; Bauer, S. and Roots, I. (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295.
170. Saeki, M.; Saito, Y.; Nakamura, T.; Murayama, N.; Kim, S. R.; Ozawa, S.; Komamura, K.; Ueno, K.; Kamakura, S.; Nakajima, T.; Saito, H.; Kitamura, Y.; Kamatani, N. and Sawada, J. (2003) Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum. Mutat. 21, 653.
171. Saeki, M.; Saito, Y.; Jinno, H.; Sai, K.; Hachisuka, A.; Kaniwa, N.; Ozawa, S.; Kawamoto, M.; Kamatani, N.; Shirao, K.; Minami, H.; Ohtsu, A.; Yoshida, T.; Saijo, N.; Komamura, K.; Kotake, T.; Morishita, H.; Kamakura, S.; Kitakaze, M.; Tomoike, H. and Sawada, J. (2005) Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab. Pharmacokinet. 20, 144-151.
172. Saeki, M.; Saito, Y.; Jinno, H.; Sai, K.; Ozawa, S.; Kurose, K.; Kaniwa, N.; Komamura, K.; Kotake, T.; Morishita, H.; Kamakura, S.; Kitakaze, M.; Tomoike, H.; Shirao, K.; Tamura, T.; Yamamoto, N.; Kunitoh, H.; Hamaguchi, T.; Yoshida, T.; Kubota, K.; Ohtsu, A.; Muto, M.; Minami, H.; Saijo, N.; Kamatani, N. and Sawada, J. (2006) Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J. 6, 63-75.
173. Sai, K.; Saeki, M.; Saito, Y.; Ozawa, S.; Katori, N.; Jinno, H.; Hasegawa, R.; Kaniwa, N.; Sawada, J.; Komamura, K.; Ueno, K.; Kamakura, S.; Kitakaze, M.; Kitamura, Y.; Kamatani, N.; Minami, H.; Ohtsu, A.; Shirao, K.; Yoshida, T. and Saijo, N. (2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75, 501-515.
174. Sata, F.; Sapone, A.; Elizondo, G.; Stocker, P.; Miller, V. P.; Zheng, W.; Raunio, H.; Crespi, C. L. and Gonzalez, F. J. (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67, 48-56.
175. Saxena, R.; Shaw, G. L.; Relling, M. V.; Frame, J. N.; Moir, D. T.; Evans, W. E.; Caporaso, N. and Weiffenbach, B. (1994) Idetification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum. Mol. Genet. 3, 923-926.
176. Schirmer, M.; Toliat, M. R.; Haberl, M.; Suk, A.; Kamdem, L. K.; Klein, K.; Brockmoller, J.; Nurnberg, P.; Zanger, U. M. and Wojnowski, L. (2006) Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenet. Genomics 16, 59-71.
177. Schwarz, U. I. (2003) Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur. J. Clin. Invest. 33, 23-30.
178. Scordo, M. G.; Aklillu, E.; Yasar, U.; Dahl, M. L.; Spina, E. and Ingelman-Sundberg, M. (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol. 52, 447-450.
179. Scott, J. and Poffenbarger, P. L. (1979) Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 28, 41-51.
180. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y. and Guengerich, F. P. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423.
181. Shintani, M.; Ieiri, I.; Inoue, K.; Mamiya, K.; Ninomiya, H.; Tashiro, N.; Higuchi, S. and Otsubo, K. (2001) Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin. Pharmacol. Ther. 70, 175-182.
182. Si, D.; Guo, Y.; Zhang, Y.; Yang, L.; Zhou, H. and Zhong, D. (2004) Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 14, 465-469.
183. Sim, S. C.; Risinger, C.; Dahl, M. L.; Aklillu, E.; Christensen, M.; Bertilsson, L. and Ingelman-Sundberg, M. (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103-113.
184. Soyama, A.; Saito, Y.; Komamura, K.; Ueno, K.; Kamakura, S.; Ozawa, S. and Sawada, J. (2002) Novel single nucleotide polymorphisms in the CYP2D6 gene associated with CYP2D6*2 and/or CYPD6*10 alleles. Drug Metab. Pharmacokinet. 17, 475-478.
185. Soyama, A.; Kubo, T.; Miyajima, A.; Saito, Y.; Shiseki, K.; Komamura, K.; Ueno, K.; Kamakura, S.; Kitakaze, M.; Tomoike, H.; Ozawa; S. and Sawada, J. (2004) Novel nonsynonymous single nucleotide polymorphisms in the CYP2D6 gene. Drug Metab. Pharmacokinet. 19, 313-319.
186. Soyama, A.; Saito, Y.; Kubo, T.; Miyajima, A.; Ohno, Y.; Komamura, K.; Ueno, K.; Kamakura, S.; Kitakaze, M.; Tomoike, H.; Ozawa, S. and Sawada, J. (2006a) Sequence-based analysis of the CYP2D6*36CYP2D6*10 tandem-type arrangement, a major CYP2D6*10 haplotype in the Japanese population. Drug Metab. Pharmacokinet. 21, 208-216.
187. Soyama, A.; Saito, Y.; Ohno, Y.; Komamura, K.; Kamakura, S.; Kitakaze, M.; Tomoike, H.; Ozawa, S. and Sawada, J. (2006b) A novel defective CYP2D6 haplotype harboring single-type *36 and chimeric CYP-REP7/6 and CYP-REP7/6 diversity in Japanese. Drug Metab. Pharmacokinet. 21, 395-405.
188. Steen, V. M.; Molven, A.; Aarskog, N. K. and Gulbrandsen, A. K. (1995) Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Hum. Mol. Genet. 4, 2251-2257.
189. Sugatani, J.; Yamakawa, K.; Yoshinari, K.; Machida, T.; Takagi, H.; Mori, M.; Kakizaki, S.; Sueyoshi, T.; Negishi, M. and Miwa, M. (2002) Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem. Biophys. Res. Commun. 292, 492-497.
190. Sutomo, R.; Talib, N. A.; Yusoff, N. M.; Van Rostenberghe, H.; Sadewa, A. H.; Sunarti Sofro, A. S.; Yokoyama, N.; Lee, M. J.; Matsuo, M. and Nishio, H. (2004) Screening for G71R mutation of the UGT1A1 gene in the Javanese-Indonesian and Malay-Malaysian populations. Pediatr. Int. 46, 565-569.
191. Tai, G.; Farin, F.; Rieder, M. J.; Dreisbach, A. W.; Veenstra, D. L.; Verlinde, C. L. and Rettie, A. E. (2005) In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet. Genomics 15, 475-481.
192. Takanashi, K.; Tainaka, H.; Kobayashi, K.; Yasumori, T.; Hosakawa, M. and Chiba, K. (2000) CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10, 95-104.
193. Takahashi, H.; Wilkinson, G. R.; Caraco, Y.; Muszkat, M.; Kim, R. B.; Kashima, T.; Kimura, S. and Echizen, H. (2003) Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73, 253-263.
194. Takahashi, H.; Wilkinson, G. R.; Nutescu, E. A.; Morita, T.; Ritchie, M. D.; Scordo, M. G.; Pengo, V.; Barban, M.; Padrini, R.; Ieiri, I.; Otsubo, K.; Kashima, T.; Kimura, S.; Kijima, S. and Echizen, H. (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16, 101-110.
195. Tate, S. K. and Goldstein, D. B. (2004) Will tomorrow's medicines work for everyone? Nat. Genet. 36, S34-42.
196. Tateishi, T.; Chida, M.; Ariyoshi, N.; Mizorogi, Y.; Kamataki, T. and Kobayashi, S. (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin. Pharmacol. Ther. 65, 570-575.
197. Tayeb, M. T.; Clark, C.; Ameyaw, M. M.; Haites, N. E.; Evans, D. A.; Tariq, M.; Mobarek, A.; Ofori-Adjei, D. and McLeod, H. L. (2000) CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 10, 753-756.
198. Teh, L. K.; Ismail, R.; Yusoff, R.; Hussein, A.; Isa, M. N. and Rahman, A. R. (2001) Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J. Clin. Pharm. Ther. 26, 205-211.
199. Thomas, S. S.; Li, S. S.; Lampe, J. W.; Potter, J. D. and Bigler, J. (2006) Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Hum. Mutat. 27, 717.
200. Thompson, E. E.; Kuttab-Boulos, H.; Witonsky, D.; Yang, L.; Roe, B. A. and Di Rienzo, A. (2004) CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75, 1059-1069.
201. Thompson, E. E.; Kuttab-Boulos, H.; Yang, L.; Roe, B. A. and Di Rienzo, A. (2006) Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J. 6, 105-114.
202. Thummel, K. E. and Wilkinson, G. R. (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430.
203. Tirona, R. G.; Lee, W.; Leake, B. F.; Lan, L. B.; Cline, C. B.; Lamba, V.; Parviz, F.; Duncan, S. A.; Inoue, Y.; Gonzalez, F. J.; Schuetz, E. G. and Kim, R. B. (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat. Med. 9, 220-224.
204. Toscano, C.; Klein, K.; Blievernicht, J.; Schaeffeler, E.; Saussele, T.; Raimundo, S.; Eichelbaum, M.; Schwab, M. and Zanger, U. M. (2006) Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet. Genomics 16, 755-766.
205. Tracy, T. S.; Hutzler, J. M.; Haining, R. L.; Rettie, A. E.; Hummel, M. A. and Dickmann, L. J. (2002) Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab. Dispos. 30, 385-390.
206. Tsuzuki, D.; Takemi, C.; Yamamoto, S.; Tamagake, K.; Imaoka, S.; Funae, Y.; Kataoka, H.; Shinoda, S. and Narimatsu, S. (2001) Functional evaluation of cytochrome P450 2D6 with Gly42Arg substitution expressed in Saccharomyces cerevisiae. Pharmacogenetics 11, 709-718.
207. Tukey, R. H. and Strassburg, C. P. (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40, 581-616.
208. Tyndale, R.; Aoyama, T.; Broly, F.; Matsunaga, T.; Inaba, T.; Kalow, W.; Gelboin, H. V.; Meyer, U. A. and Gonzalez, F. J. (1991) Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1, 26-32.
209. van Schaik, R. H.; de Wildt, S. N.; van Iperen, N. M.; Uitterlinden, A. G.; van den Anker, J. N. and Lindemans, J. (2000) CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin. Chem. 46, 1834-1836.
210. van Schaik, R. H.; van der Heiden, I. P.; van den Anker, J. N. and Lindemans, J. (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin. Chem. 48, 1668-1671.
211. Veenstra, D. L.; Blough, D. K.; Higashi, M. K.; Farin, F. M.; Srinouanprachan, S.: Rieder, M. J. and Rettie, A. E. (2005) CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin. Pharmacol. Ther. 77, 353-364.
212. Villeneuve, L.; Girard, H.; Fortier, L. C.; Gagne, J. F. and Guillemette, C. (2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J. Pharmacol. Exp. Ther. 307, 117-128.
213. Walker, A. H.; Jaffe, J. M.; Gunasegaram, S.; Cummings, S. A.; Huang, C. S.; Chem, H. D.; Olopade, O. I.; Weber, B. L. and Rebbeck, T. R. (1998) Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Hum. Mutat. 12, 289.
214. Walton, R.; Kimber, M.; Rockett, K.; Trafford, C.; Kwiatkowski, D. and Sirugo, G. (2005) Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10. Nat. Genet. 37, 915-916.
215. Wandel, C.; Witte, J. S.; Hall, J. M.; Stein, C. M.; Wood, A. J. and Wilkinson, G. R. (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin. Pharmacol. Ther. 68, 82-91.
216. Wang, S.-L.; Huang, J.-d.; Lai, M.-D.; Liu, B.-H. and Lai, M.-L. (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin. Pharmacol. Ther. 53, 410-418.
217. Wang, S. L.; Huang, J.; Lai, M. D. and Tsai, J. J. (1995) Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5, 37-42.
218. Wang, A.; Yu, B. N.; Luo, C. H.; Tan, Z. R.; Zhou, G.; Wang, L. S.; Zhang, W.; Li, Z.; Liu, J. and Zhou, H. H. (2005) Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur. J. Clin. Pharmacol. 60, 843-848.
219. Wen, S.; Wang, H.; Ding, Y.; Liang, H. and Wang, S. (2004) Screening of 12 SNPs of CYP3A4 in a Chinese population using oligonucleotide microarray. Genet. Test 8, 411-416.
220. Wennerholm, A.; Johansson, I.; Hidestrand, M.; Bertilsson, L.; Gustafsson, L. L. and Ingelman-Sundberg, M. (2001) Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 11, 417-427.
221. Wennerholm, A.; Dandara, C.; Sayi, J.; Svenson, J.-O.; Abdi, Y. A.; Ingelman-Sundberg, M.; Bertilsson, L.; Hasler, J. and Gustufsson, L. L. (2002) The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity. Clin. Pharmacol. Ther. 71, 77-88.
222. Westlind, A.; Lofberg, L.; Tindberg, N.; Andersson, T. B. and Ingelman-Sundberg, M. (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun. 259, 201-205.
223. Westlind-Johnsson, A.; Hermann, R.; Huennemeyer, A.; Hauns, B.; Lahu, G.; Nassr, N.; Zech, K.; Ingelman-Sundberg, M. and von Richter, O. (2006) Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin. Pharmacol. Ther. 79, 339-349.
224. Wong, M.; Balleine, R. L.; Collins, M.; Liddle, C.; Clarke, C. L. and Gurney, H. (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin. Pharmacol. Ther. 75, 529-538.
225. Wrighton, S. A.; VandenBranden, M. and Ring, B. J. (1996) The human drug metabolizing cytochromes P450. J. Pharmacokinet. Biopharm. 24, 461-473.
226. Xiao, Z. S.; Goldstein, J. A.; Xie, H. G.; Blaisdell, J.; Wang, W.; Jiang, C. H.; Yan, F. X.; He, N.; Huang, S. L.; Xu, Z. H. and Zhou, H. H. (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281, 604-609.
227. Yamanaka, H.; Nakajima, M.; Katoh, M.; Hara, Y.; Tachibana, O.; Yamashita, J.; McLeod, H. L. and Yokoi, T. (2004) A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14, 329-332.
228. Yamazaki, H.; Kiyotani, K.; Tsubuko, S.; Matsunaga, M.; Fujieda, M.; Saito, T.; Miura, J.; Kobayashi, S. and Kamataki, T. (2003) Two novel haplotypes of CYP2D6 gene in a Japanese population. Drug Metab. Pharmacokinet. 18, 269-271.
229. Yasar, U.; Aklillu, E.; Canaparo, R.; Sandberg, M.; Sayi, J.; Roh, H. K. and Wennerholm, A. (2002a) Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Eur. J. Clin. Pharmacol. 58, 555-558.
230. Yasar, U.; Lundgren, S.; Eliasson, E.; Bennet, A.; Wiman, B.; de Faire, U. and Rane, A. (2002b) Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun. 299, 25-28.
231. Yokoi, T.; Kosaka, Y.; Chida, M.; Chiba, K.; Nakamura, H.; Ishizaki, T.; Kinoshita, M.; Sato, K.; Gonzalez, F. J. and Kamataki, T. (1996) A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 6, 395-401.
232. Yokota, H.; Tamura, S.; Furuya, H.; Kimura, S.; Watanabe, M.; Kanazawa, I.; Kondo, I. and Gonzalez, F. J. (1993) Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 3, 256-263.
233. Yoon, Y.-R.; Cha, I.-J.; Shon, J.-H.; Kim, K.-A.; Cha, Y.-N.; Jang, I.-J.; Park, C.-W.; Shin, S.-G.; Flockhart, D. A. and Shin, J.-G. (2000) Relationship of paroxetine disposition to metoprorol metabolic ratio and CYP2D6*19 genotype of Korean subjects. Clin. Pharmacol. Ther. 67, 567-576.
234. Yoon, Y. R.; Shon, J. H.; Kim, M. K.; Lim, Y. C.; Lee, H. R.; Park, J. Y.; Cha, I. J. and Shin, J. G. (2001) Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol. 51, 277-280.
235. Yusoff, S.; Van Rostenberghe, H.; Yusoff, N. M.; Talib, N. A.; Ramli, N.; Ismail, N. Z.; Ismail, W. P.; Matsuo, M. and Nishio, H. (2006) Frequencies of A(TA)7TAA, G71R, and G493R mutations of the UGT1A1 gene in the Malaysian population. Biol. Neonate 89, 171-176.
236. Zanger, U. M.; Fischer, J.; Raimundo, S.; Stuven, T.; Evert, B. O.; Schwab, M. and Eichelbaum, M. (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11, 573-585.
237. Zeigler-Johnson, C. M.; Walker, A. H.; Mancke, B.; Spangler, E.; Jalloh, M.; McBride, S.; Deitz, A.; Malkowicz, S. B.; Ofori-Adjei, D.; Gueye, S. M. and Rebbeck, T. R. (2002) Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum. Hered. 54, 13-21.
238. Zeigler-Johnson, C.; Friebel, T.; Walker, A. H.; Wang, Y.; Spangler, E.; Panossian, S.; Patacsil, M.; Aplenc, R.; Wein, A. J.; Malkowicz, S. B. and Rebbeck, T. R. (2004) CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 64, 8461-8467.
239. Zhao, F.; Loke, C.; Rankin, S. C.; Guo, J. Y.; Lee, H. S.; Wu, T. S.; Tan, T.; Liu, T. C.; Lu, W. L.; Lim, Y. T.; Zhang, Q.; Goh, B. C. and Lee, S. C. (2004) Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 76, 210-219.